These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 21205831

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C, Low JA.
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER.
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [Abstract] [Full Text] [Related]

  • 5. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
    Sandhu SK, Yap TA, de Bono JS.
    Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
    [Abstract] [Full Text] [Related]

  • 6. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y, Calvert H.
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [Abstract] [Full Text] [Related]

  • 7. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM, Szabó C.
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [Abstract] [Full Text] [Related]

  • 8. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
    Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL.
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors.
    Gaymes TJ, Shall S, Farzaneh F, Mufti GJ.
    Haematologica; 2008 Dec; 93(12):1886-9. PubMed ID: 18838476
    [Abstract] [Full Text] [Related]

  • 12. [Clinical development of PARP inhibitors].
    Toyoda M, Minami H.
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):519-24. PubMed ID: 22504675
    [Abstract] [Full Text] [Related]

  • 13. BRCA in breast cancer: from risk assessment to therapeutic prediction.
    Diamond JR, Borges VF, Eckhardt SG, Jimeno A.
    Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
    [Abstract] [Full Text] [Related]

  • 14. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity.
    Kuo ML, Shen SC, Yang CH, Chuang SE, Cheng AL, Huang TS.
    Oncogene; 1998 Oct 29; 17(17):2225-34. PubMed ID: 9811453
    [Abstract] [Full Text] [Related]

  • 15. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
    Sandhu SK, Yap TA, de Bono JS.
    Curr Drug Targets; 2011 Dec 29; 12(14):2034-44. PubMed ID: 21777194
    [Abstract] [Full Text] [Related]

  • 16. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S, Thomas HD, Mitchell J, Curtin NJ.
    Br J Radiol; 2008 Oct 29; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [Abstract] [Full Text] [Related]

  • 17. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K, Low JA.
    Clin Cancer Res; 2007 Mar 01; 13(5):1383-8. PubMed ID: 17332279
    [Abstract] [Full Text] [Related]

  • 18. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
    Masutani M, Nakagama H, Sugimura T.
    Cell Mol Life Sci; 2005 Apr 01; 62(7-8):769-83. PubMed ID: 15868402
    [Abstract] [Full Text] [Related]

  • 19. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM, Willmore E, Austin CA, Curtin NJ.
    Clin Cancer Res; 2005 Dec 01; 11(23):8449-57. PubMed ID: 16322308
    [Abstract] [Full Text] [Related]

  • 20. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.
    Ashworth A.
    J Clin Oncol; 2008 Aug 01; 26(22):3785-90. PubMed ID: 18591545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.